Follistatin 315 — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Follistatin 315

Also known as: FST-315, FS-315, FS315, Follistatin-315, FST315, hFS-315, rhFS-315

Endogenous glycoprotein; activin-binding protein; TGF-β superfamily antagonist

Research chemicalLast updated: October 31, 2026Based on 21 peer-reviewed studies

What it is

Researchers study Follistatin-315 for its role in muscle growth, liver regeneration, and bone repair by blocking the body's natural muscle-limiting signals. It's investigated as a potential therapy for muscle wasting diseases. No FDA-approved therapeutic use; prohibited by WADA; evidence comes primarily from animal models and lab studies.

The scientific side

Follistatin 315 (FS-315) is a 315 amino acid glycoprotein originating from an alternatively spliced mRNA of the follistatin gene (PMID 3153465, PMID 3365249). It functions as a high-affinity activin-binding protein that neutralizes the biological actions of activin by forming an inactive complex. FS-315 has a lower affinity for activin A (Kd ~432 pM) compared to FS-288 (Kd ~46.5 pM), and accordingly shows weaker inhibition of activin-induced transcriptional responses. Unlike the truncated FS-288 isoform, FS-315 possesses a 27 amino acid carboxyl-terminal extension that confers no affinity for cell-surface heparan sulfate proteoglycans, causing it to be secreted freely into the medium rather than remaining cell-surface-associated. FS-315 can also bind and antagonize other TGF-β superfamily members including myostatin, thereby influencing muscle mass. In the liver, FS-315 has been reported to block activin A-mediated inhibition of hepatocyte proliferation and may promote liver regeneration. Additionally, follistatin-315 blunts hepcidin induction by inflammatory stimuli in vivo by inhibiting activin B-driven SMAD1/5/8 signaling.

Class: Endogenous glycoprotein; activin-binding protein; TGF-β superfamily antagonist

Administration & storage

Administration
Intravenous infusion in rats (PMID: 15782995)Intramuscular injection via recombinant AAV vector in mice (PMID: 33869993)
Storage
No specific storage conditions for FS-315 are described in the reviewed abstracts.
Cautions
No approved pharmaceutical formulations of follistatin are currently available; black market products labeled 'follistatin 315' or 'follistatin 344' have been found to contain His-tagged recombinant protein, oligomers, and in some cases unrelated peptides such as MGF or GHRP-2 rather than follistatin.,FS-315 is prohibited under WADA 2019 List of Prohibited Substances and Methods, chapter S4.,Native FST315 has poor pharmacokinetic properties when administered parenterally, with very short half-life and low systemic exposure in animal models; dose-response relationships are not well characterized for exogenous administration.,Mice expressing only FST-315 (lacking FST-288) showed reproductive abnormalities including reduced follicles, absent corpora lutea, and ovarian-uterine inflammation, indicating that isoform balance is important for reproductive health.,Sterile technique is required for any injectable preparation to prevent contamination and infection risk.

Legal & regulatory status

US FDA

Not stated in reviewed literature — requires manual verification. No approved pharmaceutical formulations noted in reviewed literature.

WADA

Prohibited — listed under chapter S4 of the WADA 2019 List of Prohibited Substances and Methods.

Health Canada

Not stated in reviewed literature — requires manual verification.